DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
01 1Dr. Reddy's Laboratories Limited
02 2Amphastar Nanjing Pharmaceuticals, Inc.
03 1Aurobindo Pharma Limited
04 1Biocon Limited
05 2Chengdu Shengnuo Biopharm Co. Ltd.
06 1DARMERICA, LLC
07 1FRESENIUS KABI IPSUM SRL
08 1Fujian Genohope Biotech Ltd.
09 2Hangzhou Sinodo Pharm Technology Co.,Ltd
10 1Hubei JXbio Pharmaceutical Co., Ltd
11 9Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)
12 1Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
13 1Nanjing Xingyin Pharmaceutical Group Co.,Ltd
14 1Novo Nordisk A/S
15 1Polypeptide Laboratories Inc
16 1Qingdao Biopeptek Co., Ltd.
17 1ScinoPharm Taiwan Ltd.
18 1Shanghai Ambiopharm, Inc
19 1Sinopep-Allsino Biopharmaceutical Co., Ltd.
20 1Zhejiang Peptites Biotech Co., Ltd.
01 3LIRAGLUTIDE
02 27Liraglutide
03 1liraglutide
01 14China
02 1Denmark
03 3India
04 1Sweden
05 1Switzerland
06 1Taiwan
07 7U.S.A
08 3Blank
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-022
Start Marketing Date : 2020-06-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2024-11-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2024-12-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2024-12-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2024-12-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2024-12-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2021-12-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2021-12-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0009
Start Marketing Date : 2016-08-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 0420-9006
Start Marketing Date : 2011-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
A Liraglutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Liraglutide, including repackagers and relabelers. The FDA regulates Liraglutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Liraglutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Liraglutide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Liraglutide supplier is an individual or a company that provides Liraglutide active pharmaceutical ingredient (API) or Liraglutide finished formulations upon request. The Liraglutide suppliers may include Liraglutide API manufacturers, exporters, distributors and traders.
click here to find a list of Liraglutide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Liraglutide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Liraglutide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Liraglutide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Liraglutide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Liraglutide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Liraglutide suppliers with NDC on PharmaCompass.
We have 18 companies offering Liraglutide
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
